Your session is about to expire
← Back to Search
Monoclonal Antibodies
Arm 1 for Plaque Psoriasis
Phase 2
Waitlist Available
Research Sponsored by Zai Lab (Hong Kong), Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 weeks
Awards & highlights
Study Summary
This trial will test different doses of a topical gel called ZL-1102 to see how well it works and how safe it is for treating chronic plaque psoriasis.
Who is the study for?
This trial is for individuals with chronic plaque psoriasis. Participants should have a stable disease state and be willing to apply the study gel as directed throughout the trial period. Specific details about who can join are not provided, but typically participants must meet certain health criteria.Check my eligibility
What is being tested?
The study is testing ZL-1102, a topical gel designed to treat plaque psoriasis by targeting IL-17A, which is involved in inflammation. Patients will be randomly assigned to receive different doses of ZL-1102 or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
Potential side effects are not listed, but since ZL-1102 targets the immune system, it may cause skin reactions at the application site or affect immune responses. The exact side effects will be monitored and recorded during the trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 20 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Efficacy of different doses of ZL-1102 compared to Vehicle at Week 16.
Secondary outcome measures
Anti-drug antibody (ADA) of ZL-1102.
Incidence of Treatment Related Adverse Events through Week 20.
Mean local tolerability scores (LTS)
+9 moreTrial Design
5Treatment groups
Active Control
Placebo Group
Group I: Arm 1Active Control1 Intervention
ZL-1102
Group II: Arm 2Active Control1 Intervention
ZL-1102
Group III: Arm 3Active Control1 Intervention
ZL-1102
Group IV: Arm 4Placebo Group1 Intervention
Vehicle
Group V: Arm 5Placebo Group1 Intervention
Vehicle
Find a Location
Who is running the clinical trial?
Zai Lab (Hong Kong), Ltd.Lead Sponsor
2 Previous Clinical Trials
160 Total Patients Enrolled
Zai Lab (US) LLCIndustry Sponsor
1 Previous Clinical Trials
140 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has the first arm of this study received approval from the Food and Drug Administration?
"Based on the information provided by our team at Power, Arm 1 has been assigned a safety rating of 2. This is because it is a Phase 2 trial where some data supports its safety but there is no evidence supporting its efficacy yet."
Answered by AI
At how many sites is this medical trial currently being conducted?
"This research project is being conducted at Zai Lab Site 7005 in Ottawa, Ontario; Zai Lab Site 5016 in Kotara, New South Wales; and Zai Lab Site 5013 in Phillip, Australian Capital Territory. Additionally, there are another 17 sites involved in this trial."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger